{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:46:06Z","timestamp":1793245566496,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["TRF-2018-11-ST2-002"],"award-info":[{"award-number":["TRF-2018-11-ST2-002"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.smim.2021.101519","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T21:53:06Z","timestamp":1642024386000},"page":"101519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Cellular and molecular diversity in Rheumatoid Arthritis"],"prefix":"10.1016","volume":"58","author":[{"given":"Felice","family":"Rivellese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2021.101519_bib0005","first-page":"1","article-title":"Rheumatoid arthritis","volume":"6736","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2021.101519_bib0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of Rheumatoid Arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2021.101519_bib0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/ken002","article-title":"Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Kristensen","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.smim.2021.101519_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.smim.2021.101519_bib0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0035","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2016","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.smim.2021.101519_bib0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/joim.12319","article-title":"Personalized medicine in rheumatoid arthritis: is the glass half full or half empty","volume":"277","author":"Huizinga","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.smim.2021.101519_bib0045","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrrheum.2011.204","article-title":"The influence of ACPA status and characteristics on the course of RA","volume":"8","author":"Willemze","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0060","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.autrev.2017.09.002","article-title":"Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons","volume":"16","author":"Alivernini","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.smim.2021.101519_bib0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/annrheumdis-2013-204603","article-title":"Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients","volume":"74","author":"Kelly","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0070","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/art.39235","article-title":"Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials","volume":"67","author":"Humby","year":"2015","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)."},{"key":"10.1016\/j.smim.2021.101519_bib0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","article-title":"Synovitis score: discrimination between chronic low-grade and high-grade synovitis","volume":"49","author":"Krenn","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.smim.2021.101519_bib0080","first-page":"1","article-title":"Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups","volume":"20","author":"Najm","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.smim.2021.101519_bib0085","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e32835fd8eb","article-title":"New learnings on the pathophysiology of RA from synovial biopsies","volume":"25","author":"Pitzalis","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0090","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.27415","article-title":"Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood","volume":"62","author":"Van Baarsen","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0095","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.smim.2021.101519_bib0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.gene.6363975","article-title":"Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair","volume":"4","author":"van der Pouw Kraan","year":"2003","journal-title":"Genes Immun."},{"key":"10.1016\/j.smim.2021.101519_bib0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2017.115","article-title":"Synovial tissue research: a state-of-the-art review","volume":"13","author":"Orr","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.smim.2021.101519_bib0120","doi-asserted-by":"crossref","unstructured":"G. Lliso-Ribera, F. Humby, M. Lewis, Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biologic therapy: results from the Pathobiology of Early Arthritis Cohort (PEAC), Ann. Rheum. Dis. (n.d.) https:\/\/doi.org\/10.1136\/annrheumdis-2019-215751.","DOI":"10.1136\/annrheumdis-2019-215751"},{"key":"10.1016\/j.smim.2021.101519_bib0125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.41184","article-title":"B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure","volume":"72","author":"Rivellese","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0130","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.41185","article-title":"Advancing rheumatoid arthritis synovial biopsy analysis: one B cell at a time","volume":"72","author":"Orange","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2021.101519_bib0140","first-page":"119","article-title":"Tertiary lymphoid organs in rheumatoid arthritis","author":"Rivellese","year":"2020","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.smim.2021.101519_bib0145","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1371\/journal.pmed.0060001","article-title":"Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium","volume":"6","author":"Humby","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.smim.2021.101519_bib0150","doi-asserted-by":"crossref","unstructured":"N. Meednu, J. Rangel-Moreno, F. Zhang, K. Escalera-Rivera, E. Corsiero, E. Prediletto, E. DiCarlo, S. Goodman, L.T. Donlin, S. Raychauduri, M. Bombardieri, C. Pitzalis, A. McDavid, J.H. Anolik, Single cell analysis of RA synovial B cells reveals a dynamic spectrum of ectopic lymphoid B cell activation and hypermutation characterized by NR4A nuclear receptor expression Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA\/SLE) Network, (n.d.). https:\/\/doi.org\/10.1101\/2021.05.14.443150.","DOI":"10.1101\/2021.05.14.443150"},{"issue":"11","key":"10.1016\/j.smim.2021.101519_bib0155","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/art.23966","article-title":"Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint","volume":"58","author":"Manzo","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0160","first-page":"110","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"a Rao","year":"2017","journal-title":"Nat. Publ. Gr."},{"key":"10.1016\/j.smim.2021.101519_bib0165","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1136\/annrheumdis-2015-208356","article-title":"Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs","volume":"75","author":"Corsiero","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","article-title":"The B cell response to citrullinated antigens in the development of rheumatoid arthritis","volume":"14","author":"Scherer","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0175","series-title":"Europe PMC Funders Group Diversity, Mechanisms and Significance of Macrophage Plasticity","first-page":"123","author":"Locati","year":"2021"},{"key":"10.1016\/j.smim.2021.101519_bib0180","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101519_bib0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41584-020-00570-2","article-title":"Location, location, location: how the tissue microenvironment affects inflammation in RA","volume":"17","author":"Buckley","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2021.101519_bib0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.joca.2015.11.021","article-title":"Dickkopf-3 is upregulated in osteoarthritis and has a chondroprotective role","volume":"24","author":"Snelling","year":"2016","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.smim.2021.101519_bib0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2021.101519_bib0205","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.smim.2021.101519_bib0210","series-title":"Notch Signalling Drives Synovial Fibroblast Identity and Arthritis Pathology","author":"Wei","year":"2020"},{"key":"10.1016\/j.smim.2021.101519_bib0215","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa2004114","article-title":"RNA identification of PRIME cells predicting rheumatoid arthritis flares","volume":"383","author":"Orange","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2021.101519_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2090","article-title":"Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients","volume":"8","author":"Lindberg","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.smim.2021.101519_bib0225","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2007.081950","article-title":"Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients","volume":"67","author":"Van Der Pouw Kraan","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0230","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/rheumatology\/ken261","article-title":"The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)","volume":"47","author":"Buch","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2021.101519_bib0235","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor \u03b1 expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0240","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/ard.2008.089284","article-title":"Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Ca\u00f1ete","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0245","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/art.24913","article-title":"The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study","volume":"60","author":"Klaasen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0250","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard.2009.108324","article-title":"Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade","volume":"69","author":"Rooney","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0255","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0260","doi-asserted-by":"crossref","first-page":"102738","DOI":"10.1016\/j.autrev.2020.102738","article-title":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019 Consensus","volume":"20","author":"Giacomelli","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.smim.2021.101519_bib0265","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2021.101519_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2678","article-title":"Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis","volume":"11","author":"Badot","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.smim.2021.101519_bib0275","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3899\/jrheum.090348","article-title":"Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers","volume":"36","author":"Bresnihan","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0280","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/ard.2008.091876","article-title":"Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study","volume":"68","author":"Buch","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011310","article-title":"The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis","volume":"5","author":"Lindberg","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2021.101519_bib0290","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/art.30221","article-title":"Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia","volume":"63","author":"Kennedy","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0295","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10067-011-1833-z","article-title":"Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis","volume":"30","author":"Kanbe","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.smim.2021.101519_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-0919-z","article-title":"Higher expression of TNFa\u03b1-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy","volume":"18","author":"De Groof","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.smim.2021.101519_bib0305","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","article-title":"Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0310","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/ard.62.8.715","article-title":"Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis","volume":"62","author":"Haringman","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0315","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/art.11098","article-title":"Tumor necrosis factor? Blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue","volume":"48","author":"Smeets","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0320","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/art.20664","article-title":"Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis","volume":"50","author":"Gerlag","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2003.020347","article-title":"A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis","volume":"64","author":"Van Holten","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0330","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2004.029751","article-title":"Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis","volume":"64","author":"Haringman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0335","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0340","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","article-title":"Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation","volume":"46","author":"Vergunst","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.smim.2021.101519_bib0345","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/art.23591","article-title":"Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial","volume":"58","author":"Vergunst","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2021.101519_bib0350","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/annrheumdis-2011-200298","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study","volume":"71","author":"Boumans","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.smim.2021.101519_bib0355","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00011-019-01218-y","article-title":"Toreforant, an orally active histamine H 4 -receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study","volume":"68","author":"Boyle","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.smim.2021.101519_bib0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: towards patient-centric precision medicine","author":"Pitzalis","year":"2020","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532321000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532321000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:21:23Z","timestamp":1760916083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532321000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":72,"alternative-id":["S1044532321000506"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2021.101519","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and molecular diversity in Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2021.101519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101519"}}